Research-grade reagents for malaria and parasitic disease research — primarily targeting Plasmodium species (P. falciparum, P. vivax, P. berghei), with additional coverage of Cryptosporidium, Toxoplasma, Trypanosoma, and Opisthorchis. Our portfolio includes recombinant antibodies against key vaccine and blood-stage antigens (CSP, MSP, PfEMP1, VAR2CSA), InVivoMAb functional-grade clones for in vivo transmission-blocking studies, and His-tagged recombinant proteins for immunization and assay development. RUO
All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.
1. Beeson JG, Kurtovic L, Molina-Cruz A, et al. The RTS,S malaria vaccine: current impact and foundation for the future. Sci Transl Med. 2022;14(671):eabo6646. DOI
2. Cockburn IA, Seder RA. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat Immunol. 2018;19(11):1199-1211. DOI
E. coli
P16665
Met1-Ala177
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Treponema pallidum
E. coli
P29722
Cys22-Lys156
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Treponema pallidum
E. coli
P16055, P07643, P29723
TPP15 [Ser19-Arg141] + tmpA [Gly20-Arg345] + TPP47 [Gly21-Gln434]
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Treponema pallidum
E. coli
P29723
Cys20-Gln434
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Treponema pallidum
E. coli
P07643
Ser21-Arg345
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Treponema pallidum
Treponema pallidum
ELISA, IHC, WB
Rabbit
IgG
Plasma, Serum
0.65 ng/mL
1.56 - 100 ng/mL
Plasma, Serum
0.65 ng/mL
1.56 - 100 ng/mL
Plasma, Serum
0.65 ng/mL
1.56 - 100 ng/mL